Credit Suisse 12/04/2010 1 Outperform $40.50 12.6%
With 18 months worth of clinical data about the potential use of IVIG in Alzheimer's disease soon to be reported the broker suggests investing in the company gives a free option over this potential.
While a low case with respect to any blue sky is most likely in its view the broker sees enough value in the stock to retain its Outperform rating. Target unchanged at $40.50.
Target price is $40.50 Current Price is $36.08 Difference: $4.42
If CSL meets the Credit Suisse target it will return approximately 12% (excluding dividends, fees and charges).
Credit Suisse 12/04/2010 1 Outperform $40.50 12.6%With 18 months...
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$311.70 |
Change
0.580(0.19%) |
Mkt cap ! $150.6B | |||
| Open | High | Low | Value | Volume |
| $308.37 | $311.70 | $307.33 | $411.6M | 1.374M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 55 | $310.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $311.74 | 904 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |